Acasti Pharma Inc
Research Acasti Pharma Inc (GRCE) on Bullrun: market cap USD 32.87M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGRCE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 32.87M
- Financial periodFY2026
- RevenueUSD 0
- Net income-USD 7.79M
- Free cash flow-USD 8.87M
Valuation Snapshot
latest market cap is USD 32.87M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 0 | -USD 7.79M | -USD 8.87M | n/a | -0.47 | USD 16.98M | n/a | USD 63.90M |
| FY2025 | USD 0 | -USD 9.57M | -USD 14.90M | n/a | -0.79 | USD 22.13M | n/a | USD 66.61M |
| FY2024 | USD 0 | -USD 12.85M | -USD 12.36M | n/a | -1.35 | USD 23.01M | USD 0 | USD 61.74M |
| FY2023 | USD 0 | -USD 42.43M | -USD 15.93M | n/a | -5.71 | USD 27.88M | USD 485.00K | USD 67.96M |
| FY2022 | USD 100.00M | -USD 9.82M | -USD 17.23M | 100.0% | -0.27 | USD 30.34M | USD 295.00K | USD 108.27M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 32.87M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 53.54M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 37.92M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 27.16M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 22.31M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 55.80M | n/a | n/a | n/a |
About Acasti Pharma Inc
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Acasti Pharma Inc's market cap?
Acasti Pharma Inc's market capitalization is USD 32.87M.
What does Acasti Pharma Inc do?
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc.